IDYA
IDEAYA Biosciences, Inc.
Price Chart
No historical data available
Latest Quote
$33.25
-1.46 (-4.21%)
Current Price
| Previous Close | $34.71 |
| Open | $34.95 |
| Day High | $35.00 |
| Day Low | $32.52 |
| Volume | 740,578 |
Stock Information
| Shares Outstanding | 96.49M |
| Total Debt | $29.31M |
| Cash Equivalents | $828.96M |
| Revenue | $234.13M |
| Net Income | $-175.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.21B |
| EPS (TTM) | $-1.94 |
| Exchange | NMS |
Recent Price History
No history data available. Data will be fetched automatically.
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on IDYA.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $218,710,000 | $7,000,000 | $23,385,000 | $50,931,000 |
| Operating Revenue | $218,710,000 | $7,000,000 | $23,385,000 | $50,931,000 |
| Expenses | ||||
| Total Expenses | $378,023,000 | $333,975,000 | $157,814,000 | $113,433,000 |
| Net Non Operating Interest Income Expense | $45,615,000 | $52,498,000 | $21,468,000 | $3,847,000 |
| Operating Expense | $378,023,000 | $333,975,000 | $157,814,000 | $113,433,000 |
| General And Administrative Expense | $63,319,000 | $39,302,000 | $28,306,000 | $23,897,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Interest Income | $45,615,000 | $52,498,000 | $21,468,000 | $3,847,000 |
| Interest Income | $45,615,000 | $52,498,000 | $21,468,000 | $3,847,000 |
| Normalized Income | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Income From Continuing And Discontinued Operation | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Total Operating Income As Reported | $-159,313,000 | $-326,975,000 | $-134,429,000 | $-62,502,000 |
| Net Income Common Stockholders | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Income | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Income Including Noncontrolling Interests | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Net Income Continuous Operations | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Pretax Income | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Interest Income Non Operating | $45,615,000 | $52,498,000 | $21,468,000 | $3,847,000 |
| Operating Income | $-159,313,000 | $-326,975,000 | $-134,429,000 | $-62,502,000 |
| Per Share | ||||
| Diluted EPS | $-1.28 | $-3.36 | $-1.96 | $-1.42 |
| Basic EPS | $-1.28 | $-3.36 | $-1.96 | $-1.42 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-154,720,000 | $-323,141,000 | $-130,421,000 | $-58,987,000 |
| Reconciled Depreciation | $4,593,000 | $3,834,000 | $4,008,000 | $3,515,000 |
| EBITDA (Bullshit earnings) | $-154,720,000 | $-323,141,000 | $-130,421,000 | $-58,987,000 |
| EBIT | $-159,313,000 | $-326,975,000 | $-134,429,000 | $-62,502,000 |
| Diluted Average Shares | $88,485,238 | $81,678,069 | $57,519,929 | $41,444,696 |
| Basic Average Shares | $88,485,238 | $81,678,069 | $57,519,929 | $41,444,696 |
| Diluted NI Availto Com Stockholders | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Research And Development | $314,704,000 | $294,673,000 | $129,508,000 | $89,536,000 |
| Selling General And Administration | $63,319,000 | $39,302,000 | $28,306,000 | $23,897,000 |
| Other Gand A | $63,319,000 | $39,302,000 | $28,306,000 | $23,897,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $2,159,000 |
Fetched: 2026-10-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Total Assets | $1,109,324,000 | $1,124,091,000 | $649,316,000 | $387,969,000 |
| Total Non Current Assets | $442,597,000 | $434,378,000 | $116,684,000 | $17,515,000 |
| Other Non Current Assets | $1,015,000 | $805,000 | $782,000 | $205,000 |
| Investmentin Financial Assets | $410,297,000 | $405,832,000 | $107,492,000 | $8,317,000 |
| Current Assets | $666,727,000 | $689,713,000 | $532,632,000 | $370,454,000 |
| Other Current Assets | $21,366,000 | $13,394,000 | $7,500,000 | $5,414,000 |
| Receivables | $5,973,000 | $0 | $18,000 | $211,000 |
| Other Receivables | $5,973,000 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $639,388,000 | $676,319,000 | $525,114,000 | $364,829,000 |
| Cash And Cash Equivalents | $112,825,000 | $84,378,000 | $157,018,000 | $68,632,000 |
| Accounts Receivable | - | $3,000 | $18,000 | $211,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $27,914,000 | $19,171,000 | $2,872,000 | $3,482,000 |
| Long Term Debt And Capital Lease Obligation | $27,575,000 | $18,873,000 | $1,125,000 | $1,611,000 |
| Current Debt And Capital Lease Obligation | $339,000 | $298,000 | $1,747,000 | $1,871,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $86,390,000 | $64,944,000 | $28,226,000 | $38,514,000 |
| Total Non Current Liabilities Net Minority Interest | $27,575,000 | $18,873,000 | $1,125,000 | $6,796,000 |
| Current Liabilities | $58,815,000 | $46,071,000 | $27,101,000 | $31,718,000 |
| Payables And Accrued Expenses | $58,476,000 | $45,773,000 | $25,354,000 | $21,279,000 |
| Payables | $17,584,000 | $15,421,000 | $6,598,000 | $4,280,000 |
| Accounts Payable | $17,584,000 | $15,421,000 | $6,598,000 | $4,280,000 |
| Non Current Deferred Liabilities | - | - | $0 | $5,185,000 |
| Current Deferred Liabilities | - | - | $0 | $8,568,000 |
| Equity | ||||
| Common Stock Equity | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Total Equity Gross Minority Interest | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Stockholders Equity | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Gains Losses Not Affecting Retained Earnings | $2,267,000 | $812,000 | $562,000 | $-2,871,000 |
| Other Equity Adjustments | $2,267,000 | $812,000 | $562,000 | $-2,871,000 |
| Retained Earnings | $-736,539,000 | $-622,841,000 | $-348,364,000 | $-235,403,000 |
| Other | ||||
| Ordinary Shares Number | $87,796,561 | $86,503,509 | $65,039,369 | $48,193,179 |
| Share Issued | $87,796,561 | $86,503,509 | $65,039,369 | $48,193,179 |
| Tangible Book Value | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Invested Capital | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Working Capital | $607,912,000 | $643,642,000 | $505,531,000 | $338,736,000 |
| Capital Lease Obligations | $27,914,000 | $19,171,000 | $2,872,000 | $3,482,000 |
| Total Capitalization | $1,022,934,000 | $1,059,147,000 | $621,090,000 | $349,455,000 |
| Additional Paid In Capital | $1,757,197,000 | $1,681,167,000 | $968,885,000 | $587,724,000 |
| Capital Stock | $9,000 | $9,000 | $7,000 | $5,000 |
| Common Stock | $9,000 | $9,000 | $7,000 | $5,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $27,575,000 | $18,873,000 | $1,125,000 | $1,611,000 |
| Current Capital Lease Obligation | $339,000 | $298,000 | $1,747,000 | $1,871,000 |
| Current Accrued Expenses | $40,892,000 | $30,352,000 | $18,756,000 | $16,999,000 |
| Investments And Advances | $410,297,000 | $405,832,000 | $107,492,000 | $8,317,000 |
| Available For Sale Securities | $410,297,000 | $405,832,000 | $107,492,000 | $8,317,000 |
| Net PPE | $31,285,000 | $27,741,000 | $8,410,000 | $8,993,000 |
| Accumulated Depreciation | $-14,256,000 | $-11,711,000 | $-9,611,000 | $-7,553,000 |
| Gross PPE | $45,541,000 | $39,452,000 | $18,021,000 | $16,546,000 |
| Leases | $5,124,000 | $4,913,000 | $3,321,000 | $3,321,000 |
| Other Properties | $38,130,000 | $32,288,000 | $13,701,000 | $12,227,000 |
| Machinery Furniture Equipment | $2,287,000 | $2,251,000 | $999,000 | $998,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $526,563,000 | $591,941,000 | $368,096,000 | $296,197,000 |
| Treasury Shares Number | - | - | $0 | - |
| Non Current Deferred Revenue | - | - | $0 | $5,185,000 |
| Current Deferred Revenue | - | - | $0 | $8,568,000 |
Fetched: 2026-10-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-73,466,000 | $-251,441,000 | $-117,592,000 | $-90,618,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-71,098,000 | $-247,584,000 | $-115,224,000 | $-87,175,000 |
| Cash Flow From Continuing Operating Activities | $-71,098,000 | $-247,584,000 | $-115,224,000 | $-87,175,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,368,000 | $-3,857,000 | $-2,368,000 | $-3,443,000 |
| Investing Cash Flow | $69,976,000 | $-502,559,000 | $-158,456,000 | $-33,404,000 |
| Cash Flow From Continuing Investing Activities | $69,976,000 | $-502,559,000 | $-158,456,000 | $-33,404,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $24,855,000 | $654,229,000 | $309,763,000 | $94,962,000 |
| Financing Cash Flow | $29,779,000 | $677,551,000 | $362,717,000 | $97,165,000 |
| Cash Flow From Continuing Financing Activities | $29,779,000 | $677,551,000 | $362,717,000 | $97,165,000 |
| Net Common Stock Issuance | $24,855,000 | $654,229,000 | $309,763,000 | $94,962,000 |
| Common Stock Issuance | $24,855,000 | $654,229,000 | $309,763,000 | $94,962,000 |
| Net Preferred Stock Issuance | - | $9,400,000 | $42,182,000 | $0 |
| Preferred Stock Issuance | - | $9,400,000 | $42,182,000 | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $25,000 | $69,000 | $60,000 |
| End Cash Position | $113,840,000 | $85,183,000 | $157,775,000 | $68,738,000 |
| Beginning Cash Position | $85,183,000 | $157,775,000 | $68,738,000 | $92,152,000 |
| Changes In Cash | $28,657,000 | $-72,592,000 | $89,037,000 | $-23,414,000 |
| Proceeds From Stock Option Exercised | $4,924,000 | $23,322,000 | $52,954,000 | $2,203,000 |
| Net Investment Purchase And Sale | $72,344,000 | $-498,702,000 | $-156,088,000 | $-29,961,000 |
| Sale Of Investment | $680,233,000 | $692,607,000 | $439,892,000 | $225,847,000 |
| Purchase Of Investment | $-607,889,000 | $-1,191,309,000 | $-595,980,000 | $-255,808,000 |
| Net PPE Purchase And Sale | $-2,368,000 | $-3,857,000 | $-2,368,000 | $-3,443,000 |
| Purchase Of PPE | $-2,368,000 | $-3,857,000 | $-2,368,000 | $-3,443,000 |
| Change In Working Capital | $1,868,000 | $11,546,000 | $-13,207,000 | $-42,969,000 |
| Change In Other Working Capital | $-5,973,000 | - | $-13,753,000 | $-46,479,000 |
| Change In Other Current Liabilities | $2,557,000 | $-1,369,000 | $-1,872,000 | $-1,699,000 |
| Change In Payables And Accrued Expense | $13,124,000 | $19,074,000 | $4,270,000 | $6,436,000 |
| Change In Accrued Expense | $10,427,000 | $10,794,000 | $1,635,000 | $4,572,000 |
| Change In Payable | $2,697,000 | $8,280,000 | $2,635,000 | $1,864,000 |
| Change In Account Payable | $2,697,000 | $8,280,000 | $2,635,000 | $1,864,000 |
| Change In Prepaid Assets | $-7,840,000 | $-6,159,000 | $-2,045,000 | $-2,119,000 |
| Change In Receivables | $0 | $0 | $193,000 | $892,000 |
| Changes In Account Receivables | $0 | $0 | $193,000 | $892,000 |
| Stock Based Compensation | $46,115,000 | $34,746,000 | $18,489,000 | $11,629,000 |
| Amortization Of Securities | $-9,976,000 | $-23,233,000 | $-11,553,000 | $-695,000 |
| Depreciation Amortization Depletion | $4,593,000 | $3,834,000 | $4,008,000 | $3,515,000 |
| Depreciation And Amortization | $4,593,000 | $3,834,000 | $4,008,000 | $3,515,000 |
| Depreciation | $4,593,000 | $3,834,000 | $4,008,000 | $3,515,000 |
| Net Income From Continuing Operations | $-113,698,000 | $-274,477,000 | $-112,961,000 | $-58,655,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
| Change In Other Current Assets | - | - | - | $1,414,000 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-10-23